SI9620076B - Stabilni reagenti za pripravo radiofarmacevtikov - Google Patents

Stabilni reagenti za pripravo radiofarmacevtikov Download PDF

Info

Publication number: SI9620076B
Authority: SI; Slovenia
Prior art keywords: substituted; group; independently selected; occurrence; alkyl
Prior art date: 1995-06-07

Application number

SI9620076A

Other languages

English (en)

Slovenian (sl)

Other versions

SI9620076A (sl

Inventor

Michael Sworin

Milind Rajopadhye

Thomas David Harris

David Scott Edwards

Edward Hollister Cheesman

Shuang Liu

Original Assignee

Dupont Pharmaceuticals Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

2000-02-29

1996-06-07 Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company

1998-08-31 Publication of SI9620076A publication Critical patent/SI9620076A/sl

2000-02-29 Publication of SI9620076B publication Critical patent/SI9620076B/sl

Links

239000003153 chemical reaction reagent Substances 0.000 title claims abstract 12
239000012217 radiopharmaceutical Substances 0.000 title claims abstract 5
229940121896 radiopharmaceutical Drugs 0.000 title claims abstract 5
230000002799 radiopharmaceutical effect Effects 0.000 title claims abstract 5
150000007857 hydrazones Chemical class 0.000 claims abstract 4
229910052739 hydrogen Inorganic materials 0.000 claims 13
125000000623 heterocyclic group Chemical group 0.000 claims 12
239000001257 hydrogen Substances 0.000 claims 12
125000003118 aryl group Chemical group 0.000 claims 11
150000002431 hydrogen Chemical class 0.000 claims 8
125000000217 alkyl group Chemical group 0.000 claims 7
229910006069 SO3H Inorganic materials 0.000 claims 5
239000003446 ligand Substances 0.000 claims 5
102000004196 processed proteins & peptides Human genes 0.000 claims 5
108090000765 processed proteins & peptides Proteins 0.000 claims 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
101100294118 Caenorhabditis elegans nhr-53 gene Proteins 0.000 claims 3
239000003795 chemical substances by application Substances 0.000 claims 3
239000002464 receptor antagonist Substances 0.000 claims 3
229940044551 receptor antagonist Drugs 0.000 claims 3
101100516569 Caenorhabditis elegans nhr-85 gene Proteins 0.000 claims 2
101710091342 Chemotactic peptide Proteins 0.000 claims 2
125000002877 alkyl aryl group Chemical group 0.000 claims 2
239000000872 buffer Substances 0.000 claims 2
150000001723 carbon free-radicals Chemical class 0.000 claims 2
239000003638 chemical reducing agent Substances 0.000 claims 2
229920006395 saturated elastomer Polymers 0.000 claims 2
239000003381 stabilizer Substances 0.000 claims 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
125000005865 C2-C10alkynyl group Chemical group 0.000 claims 1
102000009123 Fibrin Human genes 0.000 claims 1
108010073385 Fibrin Proteins 0.000 claims 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
102000003800 Selectins Human genes 0.000 claims 1
108090000184 Selectins Proteins 0.000 claims 1
125000003710 aryl alkyl group Chemical group 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
229950003499 fibrin Drugs 0.000 claims 1
125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
210000000265 leukocyte Anatomy 0.000 claims 1
125000005647 linker group Chemical group 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
239000000816 peptidomimetic Substances 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
229920001184 polypeptide Polymers 0.000 claims 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 1
102000005962 receptors Human genes 0.000 claims 1
108020003175 receptors Proteins 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
229940075620 somatostatin analogue Drugs 0.000 claims 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
238000009007 Diagnostic Kit Methods 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000012216 imaging agent Substances 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
0 CC(C)C(C(N(C)[C@@](CCCNC(*)=N)C(NCC(N[C@](C1)([C@]1C(O)=O)C(NCc1cc2cc(NC(CCCCCNC(c3ccc(NN=C4CCCC4)nc3)=O)=O)c1)=O)=O)=O)=O)NC2=O Chemical compound CC(C)C(C(N(C)[C@@](CCCNC(*)=N)C(NCC(N[C@](C1)([C@]1C(O)=O)C(NCc1cc2cc(NC(CCCCCNC(c3ccc(NN=C4CCCC4)nc3)=O)=O)c1)=O)=O)=O)=O)NC2=O 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Toxicology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SI9620076A 1995-06-07 1996-06-07 Stabilni reagenti za pripravo radiofarmacevtikov SI9620076B (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/476,296 US5750088A (en)	1993-03-30	1995-06-07	Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
PCT/US1996/009766 WO1996040637A1 (en)	1995-06-07	1996-06-07	Stable reagents for the preparation of radiopharmaceuticals

Publications (2)

Publication Number	Publication Date
SI9620076A SI9620076A (sl)	1998-08-31
SI9620076B true SI9620076B (sl)	2000-02-29

Family

ID=23891282

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9620076A SI9620076B (sl)	1995-06-07	1996-06-07	Stabilni reagenti za pripravo radiofarmacevtikov

Country Status (29)

Country	Link
US (2)	US5750088A (2)
EP (1)	EP0832068B1 (2)
JP (1)	JPH11507364A (2)
KR (1)	KR19990022573A (2)
CN (1)	CN1192733A (2)
AR (1)	AR003959A1 (2)
AT (1)	ATE233241T1 (2)
AU (1)	AU718683B2 (2)
BR (1)	BR9609003A (2)
CA (1)	CA2222183A1 (2)
CZ (1)	CZ380197A3 (2)
DE (1)	DE69626392T2 (2)
EA (1)	EA000742B1 (2)
EE (1)	EE9700313A (2)
ES (1)	ES2193245T3 (2)
HR (1)	HRP960250A2 (2)
HU (1)	HUP9901469A3 (2)
IL (1)	IL118468A0 (2)
LT (1)	LT4380B (2)
LV (1)	LV12044B (2)
MX (1)	MX9709126A (2)
MY (1)	MY133974A (2)
NO (1)	NO975678L (2)
NZ (1)	NZ310799A (2)
PL (1)	PL323995A1 (2)
SI (1)	SI9620076B (2)
SK (1)	SK163497A3 (2)
WO (1)	WO1996040637A1 (2)
ZA (1)	ZA964854B (2)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0888130B1 (en) *	1996-03-13	2003-07-02	Bristol-Myers Squibb Pharma Company	New ternary radiopharmaceutical complexes
US20030124053A1 (en) *	1996-10-07	2003-07-03	Barrett John Andrew	Radiopharmaceuticals for imaging infection and inflammation
ATE240123T1 (de) *	1996-10-07	2003-05-15	Bristol Myers Squibb Pharma Co	Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen
US6416733B1 (en) *	1996-10-07	2002-07-09	Bristol-Myers Squibb Pharma Company	Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en)	1997-05-28	2002-06-11	Bristol-Myers Squibb Pharma Company	Ternary ligand complexes useful as radiopharmaceuticals
US6524553B2 (en)	1998-03-31	2003-02-25	Bristol-Myers Squibb Pharma Company	Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) *	1998-03-31	2003-03-25	Bristol-Myers Squibb Pharma Company	Pharmaceuticals for the imaging of angiogenic disorders
AU3119199A (en) *	1998-04-03	1999-10-25	Du Pont Pharmaceuticals Company	Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) *	1998-10-13	2000-06-30	Du Pont Pharm Co	A process for the preparation of a thrombus imaging agent
CA2349501A1 (en)	1998-12-18	2000-06-22	Du Pont Pharmaceuticals Company	Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en)	1998-12-18	2003-01-28	Thomas D. Harris	Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) *	1998-12-18	2001-10-10	Du Pont Pharmaceuticals Company	Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) *	1998-12-18	2004-09-21	Bristol-Myers Squibb Pharma Company	Vitronectin receptor antagonist pharmaceuticals
CA2364753A1 (en) *	1999-03-26	2000-10-05	Joel Lazewatsky	Method for localization of blood clots
US6808698B1 (en)	1999-03-26	2004-10-26	Bristol-Myers Squibb Pharma Company	Method for localization of blood clots
US6656448B1 (en)	2000-02-15	2003-12-02	Bristol-Myers Squibb Pharma Company	Matrix metalloproteinase inhibitors
US20030220646A1 (en) *	2002-05-23	2003-11-27	Thelen Sarah L.	Method and apparatus for reducing femoral fractures
US6534038B2 (en) *	2000-04-07	2003-03-18	Bristol-Myers Squibb Pharma Company	Ternary ligand complexes useful as radiopharmaceuticals
HUP0400758A3 (en)	2000-11-03	2005-02-28	Bristol Myers Squibb Pharma Co	Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
GB0031592D0 (en) *	2000-12-28	2001-02-07	Nycomed Amersham Plc	Stabilised radiopharmaceutical compositions
MXPA04001113A (es) *	2001-08-08	2004-07-08	Bristol Myers Squibb Pharma Co	Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
US6838074B2 (en)	2001-08-08	2005-01-04	Bristol-Myers Squibb Company	Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en)	2003-05-22	2007-11-20	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7319149B2 (en) *	2003-06-13	2008-01-15	Bristol-Myers Squibb Pharma Company	Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7317104B2 (en)	2003-06-13	2008-01-08	Bristol-Myers Squibb Pharma Company	Chelants and macrocyclic metal complex radiopharmaceuticals thereof
SG177216A1 (en) *	2003-07-24	2012-01-30	Bracco Imaging Spa	Stable radiopharmaceutical compositions and methods for their preparation
US20050106100A1 (en) *	2003-09-03	2005-05-19	Harris Thomas D.	Compounds containing matrix metalloproteinase substrates and methods of their use
KR20080022588A (ko) *	2005-06-30	2008-03-11	브리스톨-마이어스 스퀴브 파마 컴퍼니	영상화제로서의 히드라지드 컨쥬게이트
WO2007046411A1 (ja) *	2005-10-19	2007-04-26	Dainippon Sumitomo Pharma Co., Ltd.	イソキサゾール化合物の安定化方法
JP5148507B2 (ja) *	2005-12-20	2013-02-20	アストラゼネカ・アクチエボラーグ	Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体及びその合成法
US7465795B2 (en) *	2005-12-20	2008-12-16	Astrazeneca Ab	Compounds and uses thereof
CA2673683C (en)	2007-01-11	2014-07-29	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
TW200911760A (en) *	2007-06-19	2009-03-16	Astrazeneca Ab	Compounds and uses thereof
CA2710039C (en)	2007-12-26	2018-07-03	Critical Outcome Technologies, Inc.	Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
CA2730890C (en)	2008-07-17	2018-05-15	Critical Outcome Technologies Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
FR2940652B1 (fr) *	2008-12-29	2011-02-11	Sanofi Aventis	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
MX2011007061A (es) *	2008-12-29	2011-12-16	Sanofi Sa	Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
FR2949468B1 (fr) *	2009-08-28	2011-09-30	Sanofi Aventis	Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
HRP20140680T1 (hr)	2008-12-29	2014-10-10	Sanofi	Derivati 2-piridin-2-ilpirazol-3(2h)-ona, njihovo dobivanje i njihova upotreba u terapiji kao aktivatora hif
CA2794952C (en)	2010-04-01	2018-05-15	Critical Outcome Technologies Inc.	Compounds and method for treatment of hiv
FR2967671A1 (fr) *	2010-11-24	2012-05-25	Pf Medicament	Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) *	2019-11-22	2022-11-22	华东理工大学	吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) *	2021-03-03	2022-02-25	江苏元本生物科技有限公司	一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4427646A (en)	1981-04-02	1984-01-24	Research Corporation	Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4578079A (en)	1982-08-04	1986-03-25	La Jolla Cancer Research Foundation	Tetrapeptide
US4792525A (en)	1982-08-04	1988-12-20	La Jolla Cancer Research Foundation	Tetrapeptide
CA1300608C (en) *	1985-05-10	1992-05-12	Edward A. Deutsch	99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) *	1986-10-09	1986-11-12	Amersham Int Plc	Cationic complexes of tc-99m
US5217705A (en)	1987-09-25	1993-06-08	Neorx Corporation	Method of diagnosing blood clots using fibrin-binding proteins
AU639409B2 (en)	1987-12-10	1993-07-29	La Jolla Cancer Research Foundation	Conformationally stabilized cell adhesion peptides
AU619538B2 (en) *	1988-03-09	1992-01-30	Cis Bio International	Preparation of nitruro compounds usable as radio-pharmaceutical products
GB8808414D0 (en) *	1988-04-11	1988-05-11	Amersham Int Plc	Ligands & cationic complexes thereof with technetium-99m
AU3569189A (en)	1988-04-29	1989-11-24	New England Deaconess Hospital Corporation	Hybrid peptides and methods of their use
US5002754A (en) *	1988-06-15	1991-03-26	University Of Cincinnati	Technetium (III/II) imaging agents
WO1990003391A1 (en)	1988-09-29	1990-04-05	Biogen, Inc.	Hirudin peptides
US5066789A (en) *	1988-09-30	1991-11-19	Neorx Corporation	Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en)	1988-12-29	1993-12-14	Bio-Technology General Corp.	Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) *	1989-02-03	1989-03-22	Amersham Int Plc	Cationic complexes of technetium-99m
US5206370A (en) *	1989-02-24	1993-04-27	Johnson Matthey, Inc.	Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) *	1989-02-24	1994-02-27	Johnson Mathey Inc	Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions
US4917879A (en) *	1989-05-19	1990-04-17	University Of Cincinnati	99MTC(III) myocardial imaging agents that are effective in humans
US4957728A (en) *	1989-05-19	1990-09-18	University Of Cincinnati	Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
GB8914020D0 (en)	1989-06-19	1989-08-09	Antisoma Ltd	Synthetic peptides for use in thrombus detection
EP0410537A1 (en)	1989-07-28	1991-01-30	Merck & Co. Inc.	Fibrinogen receptor antagonists
GB8919488D0 (en) *	1989-08-29	1989-10-11	Amersham Int Plc	New cores for technetium radiopharmaceuticals
CA2026377A1 (en)	1989-10-03	1991-04-04	John L. Krstenansky	Radiolabeled anticoagulant peptides
US5086069A (en)	1990-02-05	1992-02-04	Rorer Pharmaceutical Corporation	Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) *	1990-05-14	1996-01-30	Bristol Myers Squibb Co	Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) *	1990-07-04	1992-01-10	Cis Bio Int	Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en)	1990-09-27	1995-11-27	Merck & Co Inc	Fibrinogen receptor antagonists and pharmaceutical compositions containing them
ATE152917T1 (de) *	1990-09-28	1997-05-15	Neorx Corp	Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5112594A (en) *	1991-04-04	1992-05-12	Mallinckrodt Medical, Inc.	Kit for preparing a technetium-99m myocardial imaging agent
ATE188387T1 (de)	1991-02-08	2000-01-15	Diatide Inc	Technetium-99m markierte polypeptide zur bildformung
FR2679452B1 (fr) *	1991-07-22	1993-11-12	Cis Bio International	Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) *	1991-09-27	1994-11-08	Pfizer Inc.	Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
DE69334033D1 (de)	1992-05-21	2006-07-27	Diatide Inc	Technetium-99M markierte Peptide zur Bilderzeugung von Thrombus
GB2268494B (en)	1992-07-08	1996-08-21	Kenneth Francis Prendergast	Imaging compositions
FR2698272B1 (fr) *	1992-11-20	1994-12-30	Cis Bio Int	Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) *	1993-03-30	1999-03-09	The Dupont Merck Pharmaceutical Company	Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

1995
- 1995-06-07 US US08/476,296 patent/US5750088A/en not_active Expired - Fee Related
1996
- 1996-05-30 IL IL11846896A patent/IL118468A0/xx unknown
- 1996-06-04 HR HR08/476,296A patent/HRP960250A2/hr not_active Application Discontinuation
- 1996-06-06 MY MYPI96002227A patent/MY133974A/en unknown
- 1996-06-07 HU HU9901469A patent/HUP9901469A3/hu unknown
- 1996-06-07 MX MX9709126A patent/MX9709126A/es unknown
- 1996-06-07 JP JP9501990A patent/JPH11507364A/ja not_active Ceased
- 1996-06-07 ES ES96919289T patent/ES2193245T3/es not_active Expired - Lifetime
- 1996-06-07 AT AT96919289T patent/ATE233241T1/de not_active IP Right Cessation
- 1996-06-07 PL PL96323995A patent/PL323995A1/xx unknown
- 1996-06-07 CA CA002222183A patent/CA2222183A1/en not_active Abandoned
- 1996-06-07 CN CN96196141A patent/CN1192733A/zh active Pending
- 1996-06-07 EA EA199800025A patent/EA000742B1/ru not_active IP Right Cessation
- 1996-06-07 KR KR1019970709054A patent/KR19990022573A/ko not_active Ceased
- 1996-06-07 DE DE69626392T patent/DE69626392T2/de not_active Expired - Fee Related
- 1996-06-07 WO PCT/US1996/009766 patent/WO1996040637A1/en not_active Ceased
- 1996-06-07 BR BR9609003-0A patent/BR9609003A/pt not_active Application Discontinuation
- 1996-06-07 AU AU61661/96A patent/AU718683B2/en not_active Ceased
- 1996-06-07 ZA ZA9604854A patent/ZA964854B/xx unknown
- 1996-06-07 NZ NZ310799A patent/NZ310799A/xx unknown
- 1996-06-07 SK SK1634-97A patent/SK163497A3/sk unknown
- 1996-06-07 CZ CZ973801A patent/CZ380197A3/cs unknown
- 1996-06-07 AR ARP960103028A patent/AR003959A1/es not_active Application Discontinuation
- 1996-06-07 SI SI9620076A patent/SI9620076B/sl unknown
- 1996-06-07 EP EP96919289A patent/EP0832068B1/en not_active Expired - Lifetime
- 1996-06-07 EE EE9700313A patent/EE9700313A/xx unknown
1997
- 1997-10-23 US US08/956,313 patent/US6015904A/en not_active Expired - Fee Related
- 1997-12-05 LT LT97-191A patent/LT4380B/lt not_active IP Right Cessation
- 1997-12-05 NO NO975678A patent/NO975678L/no not_active Application Discontinuation
1998
- 1998-01-28 LV LVP-97-247A patent/LV12044B/en unknown

Also Published As

Publication number	Publication date
LV12044A (lv)	1998-05-20
LV12044B (en)	1998-09-20
SK163497A3 (en)	1998-10-07
ZA964854B (en)	1997-12-08
KR19990022573A (ko)	1999-03-25
EP0832068A1 (en)	1998-04-01
ATE233241T1 (de)	2003-03-15
HRP960250A2 (en)	1997-12-31
EA199800025A1 (ru)	1998-06-25
HUP9901469A3 (en)	2000-02-28
MX9709126A (es)	1998-03-31
EA000742B1 (ru)	2000-02-28
MY133974A (en)	2007-11-30
CA2222183A1 (en)	1996-12-19
AU718683B2 (en)	2000-04-20
NO975678D0 (no)	1997-12-05
JPH11507364A (ja)	1999-06-29
ES2193245T3 (es)	2003-11-01
CZ380197A3 (cs)	1998-07-15
AU6166196A (en)	1996-12-30
WO1996040637A1 (en)	1996-12-19
AR003959A1 (es)	1998-09-30
US6015904A (en)	2000-01-18
NO975678L (no)	1998-02-06
EP0832068B1 (en)	2003-02-26
SI9620076A (sl)	1998-08-31
DE69626392T2 (de)	2004-04-22
LT97191A (en)	1998-04-27
HUP9901469A2 (hu)	1999-08-30
PL323995A1 (en)	1998-04-27
EE9700313A (et)	1998-06-15
CN1192733A (zh)	1998-09-09
LT4380B (lt)	1998-09-25
NZ310799A (en)	2000-01-28
IL118468A0 (en)	1996-09-12
BR9609003A (pt)	1999-12-14
US5750088A (en)	1998-05-12
DE69626392D1 (de)	2003-04-03

Publication	Publication Date	Title
SI9620044B (sl)	1999-02-28	Ternarni radiofarmacevtski kompleksi
AU2023203682B2 (en)	2025-07-24	Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US20230147035A1 (en)	2023-05-11	Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
ES2972148T3 (es)	2024-06-11	Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
CA2191951C (en)	2009-01-27	Monoamine, diamide, thiol-containing metal chelating agents
JP2004529884A5 (2)	2005-12-22
EP3973998B1 (en)	2023-07-26	Methods for cell labeling and medical imaging
CA3137963A1 (en)	2020-10-29	Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
US20240182382A1 (en)	2024-06-06	Aliphatic 18f-radiolabeling of a tetrazine precursor
ES2654528T3 (es)	2018-02-14	Procedimiento de preparación de un derivado de purina marcado, dicho derivado y sus usos
CN103732563B (zh)	2016-04-20	18f-糖-叶酸类
EP4291252A1 (en)	2023-12-20	Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
US20080260636A1 (en)	2008-10-23	Stabilization of radionuclide-containing compositions
ES2985919T3 (es)	2024-11-07	Agentes diagnósticos y terapéuticos dirigidos a CXCR4 con selectividad de especie reducida
CA3149598A1 (en)	2021-03-04	Novel theranostic agents for psma positive cancers
EP0053347A2 (en)	1982-06-09	Radioactive diagnostic agent and non-radioactive carrier therefor
IE920761A1 (en)	1992-09-09	Chelates, their metal complexes as well as their use in¹diagnosis and treatment
JP4723378B2 (ja)	2011-07-13	石灰化組織親和性化合物
US6342201B1 (en)	2002-01-29	Complex compounds for diagnosis of vascular diseases
KR102548998B1 (ko)	2023-06-29	혈전영상을 위한 방사성의약품 및 조성물
ES2211602T3 (es)	2004-07-16	Quelantes macrociclicos para productos metalofarmaceuticos.
JP2014511338A (ja)	2014-05-15	放射性ヨウ素化グアニジン
KR20060100200A (ko)	2006-09-20	방사선제약 화합물의 합성에 유용한 보조기
NZ792994A (en)	2025-07-25	Psma combiner and use thereof
NZ792994B2 (en)	2025-10-29	Psma combiner and use thereof